Late Stage Chronic Kidney Disease Drugs Market Report 2026

The late stage chronic kidney disease drugs market size has grown rapidly in recent years. It will grow from $7.86 billion in 2025 to $8.74 billion in 2026 at a compound annual growth rate (CAGR) of 11.1%. The growth in the historic period can be attributed to rising prevalence of chronic kidney disease, limited awareness of late-stage treatment options, increasing dialysis dependency, growing geriatric population, restricted access to specialized care.

The late stage chronic kidney disease drugs market size is expected to see rapid growth in the next few years. It will grow to $13.59 billion in 2030 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to advancement in precision medicine, integration of digital health platforms, rising adoption of novel drug therapies, increased government healthcare initiatives, growing investments in patient monitoring technologies. Major trends in the forecast period include personalized treatment protocols, novel drug formulations for late-stage ckd, symptom management optimization, patient adherence & monitoring solutions, healthcare provider decision support.

The high prevalence of chronic kidney disease is expected to drive the growth of the late-stage chronic kidney disease drug market in the coming years. Chronic kidney disease encompasses a wide range of conditions that impair the structure and function of the kidneys. Drugs used in late-stage chronic kidney disease are intended to control blood pressure, reduce protein loss, slow the progression of kidney damage, manage symptoms, and prevent complications. For example, in May 2024, according to the Centers for Disease Control and Prevention, an estimated 14% of adults in the United States, or approximately 35.5 million people, were living with chronic kidney disease. As a result, the growing prevalence of chronic kidney disease is contributing to the expansion of the late-stage chronic kidney disease drug market.

Companies operating in the late-stage chronic kidney disease drugs market are focusing on developing advanced technologies such as continuous subcutaneous infusion approaches to improve treatment effectiveness, enhance patient outcomes, and optimize drug delivery. Continuous subcutaneous infusion technology administers medication at a steady rate through a small device placed under the skin, ensuring consistent therapeutic drug levels and improving patient adherence. For instance, in January 2024, AbbVie Inc., a US-based pharmaceutical company, launched PRODUODOPA (levodopa/foscarbidopa). PRODUODOPA enables continuous infusion of levodopa, helping maintain stable dopamine levels in the bloodstream, extending periods of effective symptom control, and reducing fluctuations associated with treatment.

In January 2023, AstraZeneca, a UK-based biopharmaceutical and biotechnology company, acquired CinCor Pharma Inc. for $1.3 billion. Through this acquisition, AstraZeneca strengthened its cardiorenal pipeline with baxdrostat (CIN-107), an aldosterone synthase inhibitor under development for the treatment of chronic kidney disorders.

Major companies operating in the late stage chronic kidney disease drugs market are Pfizer Inc., Johnson & Johnson, AbbVie Inc., Bayer AG, Novartis AG, Sanofi SA, Bristol-Myers Squibb Company, AstraZeneca plc, Eli Lilly and Company, C.H. Boehringer Sohn AG & Co. KG, Amgen Inc., Novo Nordisk A/S, Teva Pharmaceutical Industries Ltd., Otsuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Company Limited, Kyowa Kirin Co Ltd., OPKO Health Inc., Akebia Therapeutics Inc., Ardelyx Inc., Pharmaxis Limited, Deltanoid Pharmaceuticals Inc., Liminal BioSciences Inc., Chinook Therapeutics Inc., Allena Pharmaceuticals Inc., Shield Therapeutics Plc.

North America was the largest region in the late-stage chronic kidney disease drugs market in 2025. The regions covered in the late stage chronic kidney disease drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the late stage chronic kidney disease drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the late-stage chronic kidney disease drugs market by increasing the cost of imported active pharmaceutical ingredients (APIs) and raw materials, leading to higher production expenses. The segments most affected include calcimimetics and potassium binders, with Asia-Pacific regions such as India and China seeing the highest impact due to manufacturing and supply chain dependencies. While tariffs pose challenges by raising drug costs, they may encourage local production and innovation, supporting the development of cost-efficient therapies and enhancing domestic manufacturing capabilities.

The late stage chronic kidney disease drugs market research report is one of a series of new reports that provides late stage chronic kidney disease drugs market statistics, including late stage chronic kidney disease drugs industry global market size, regional shares, competitors with a late stage chronic kidney disease drugs market share, detailed late stage chronic kidney disease drugs market segments, market trends and opportunities, and any further data you may need to thrive in the late stage chronic kidney disease drugs industry. This late stage chronic kidney disease drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Late-stage chronic kidney disease drugs are medications used to treat end-stage chronic kidney disease. These drugs help improve a patient’s quality of life by slowing disease progression and reducing or delaying the need for dialysis or kidney transplantation.

The main product types of late-stage chronic kidney disease drugs include calcimimetics, vitamin D, sterols, potassium binders, and calcium-based phosphate binders. Calcimimetics are a class of medications that lower parathyroid hormone (PTH) levels by allosterically activating the calcium-sensing receptor, thereby increasing calcium signaling. These drugs are used for indications such as late-stage chronic kidney disease-induced hyperparathyroidism, late-stage chronic kidney disease-induced hyperphosphatemia, and late-stage chronic kidney disease-induced hyperkalemia, and are distributed through hospital pharmacies, online pharmacies, and retail pharmacies.

The late-stage chronic kidney disease drugs market consists of sales of angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARB), and erythropoietin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.